Medical Journals

Ccr5 Blockade Modulates Inflammation and Alloimmunity in Primates.

Authors:
  • Schröder Carsten
  • Pierson Richard N
  • Nguyen Bao-Ngoc H
  • Kawka Douglas W
  • Peterson Laurence B
  • Wu Guosheng
  • Zhang Tianshu
  • Springer Martin S
  • Siciliano Sal J
  • Iliff Susan
  • Ayala Julia M
  • Lu Min
  • Mudgett John S
  • Lyons Kathy
  • Mills Sander G
  • Miller Geraldine G
  • Singer Irwin I
  • Azimzadeh Agnes M
  • DeMartino Julie A

From: Division of Cardiac Surgery, Department of Surgery, University of Maryland and Baltimore Veterans Administration Medical Center, Baltimore, MD 21201, USA.

Journal of immunology (Baltimore, Md. : 1950)

  • Publish Date: Aug 2007
  • ISSN: 0022-1767
  • Volume: 179
  • Issue: 4
  • Pages: 2289-99
  • Medium: Print
  • Language: English
  • Citation (JAMA): Schröder Carsten, Pierson Richard N, Nguyen Bao-Ngoc H, et al. Ccr5 Blockade Modulates Inflammation and Alloimmunity in Primates.. J. Immunol. Aug 2007;179:2289-99

Abstract

Pharmacologic antagonism of CCR5, a chemokine receptor expressed on macrophages and activated T cells, is an effective antiviral therapy in patients with macrophage-tropic HIV infection, but its efficacy in modulating inflammation and immunity is only just beginning to be investigated. In this regard, the recruitment of CCR5-bearing cells into clinical allografts is a hallmark of acute rejection and may anticipate chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous for a nonfunctional Delta32 CCR5 receptor rarely exhibit late graft loss. Therefore, we explored the effects of a potent, highly selective CCR5 antagonist, Merck’s compound 167 (CMPD 167), in an established cynomolgus monkey cardiac allograft model. Although perioperative stress responses (fever, diminished activity) and the recruitment of CCR5-bearing leukocytes into the graft were markedly attenuated, anti-CCR5 monotherapy only marginally prolonged allograft survival. In contrast, relative to cyclosporine A monotherapy, CMPD 167 with cyclosporine A delayed alloantibody production, suppressed cardiac allograft vasculopathy, and tended to further prolong graft survival. CCR5 therefore represents an attractive therapeutic target for attenuating postsurgical stress responses and favorably modulating pathogenic alloimmunity in primates, including man.

Mesh Headings (Keywords): Animals, Antibody Formation, Autoimmunity, Cyclosporine, Disease Models, Animal, Graft Survival, HIV Infections, Heart Transplantation, Humans, Immunosuppressive Agents, Inflammation, Isoantibodies, Kidney Transplantation, Macaca fascicularis, Macrophages, Male, Pyrazoles, Receptors, CCR5, Stress, T-Lymphocytes, Transplantation Tolerance, Transplantation, Homologous, Valine, Vascular Diseases


Check for Full Text / PubMed Unique Identifier (PMID): 17675490


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.